Palatin reports positive phase 2b results in type 2 diabetic nephropathy
Topline phase 2 data shows promise for bremelanotide in the treatment of a common diabetes complication with high unmet needs
Patient centricity
FDA grants orphan drug designation to CervoMed’s dementia drug
Neflamapimod is an oral investigational small-molecule drug designed to treat frontotemporal dementia.
AstraZeneca claims phase 3 success with combination therapy for prostate cancer
High-level results from an ongoing clinical trial make Astrazeneca’s combination treatment the first to show benefit in a subtype of prostate cancer.
How eCOA/ePRO is transforming clinical trials
A conversation with Steve Rosenberg, CEO of uMotif electronic clinical outcome assessment (eCOA) - collecting data electronically.
Brixton Biosciences: Drug-free pain relief for knee osteoarthritis
Neural Ice: Is this long-lasting pain therapy revolutionizing treatment?
Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.
Pfizer’s HYMPAVZI for Hemophilia A or B receives EU approval
The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.
Helen Harrington’s journey: Patience, passion, and problem-solving
From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of resilience and curiosity.
Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease
Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.
Tirzepatide prevents type 2 diabetes in 99% of prediabetic patients for 3 years
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to type 2 diabetes in 99% of participants.
US companies enhancing decentralized clinical trials
Traditional clinical trials usually rely on several physical trial sites to recruit and monitor patients.
The decentralized clinical trials market will grow to $25 billion by 2032
Driven by the effects of the COVID-19 pandemic, the market for decentralized clinical trials has seen a push that will lead it to more than triple in size within the next decade.
Medable and Google Cloud partner to deliver digital clinical trials technology
The partners will work together to make Medable’s digital and decentralized clinical trial platform available on Google Cloud Marketplace.
Transparency and remote options key in clinical trial engagement
A recent Lindus Health survey emphasizes the importance of patient-centered designs in clinical trials, particularly highlighting how telehealth options could improve accessibility and convenience for participants.
Gifthealth and United Digestive partner for enhanced GI care access
Gifthealth Partners with United Digestive to boost patient access and procedure prep.
Jennifer Visser-Rogers: Leading science transformation at Coronado Research
In a conversation with Professor Jennifer Visser-Rogers, chief scientific officer at Coronado Research, she shares insights on the evolving landscape of pharmaceutical development.
Abbisko’s pimicotinib hits primary endpoint in phase 3 TGCT trial
Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in China and elsewhere.
Private equity firms GHO and Ampersand acquire Avid Bioservices for $1.1 billion
Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the acquisition of Avid Bioservices.
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Starget Pharma’s AI-Driven Cancer Therapy Gains $5.1 Million Backing
Innovative radiotherapy offers a precision treatment alternative.
FDA grants accelerated approval to Novartis’ Scemblix as a first-line leukemia therapy
Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia.
Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease.
Axonis raises $115 million to overcome drug resistance in epilepsy
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
Competitors race to launch GLP-1 drugs amid soaring weight loss demand
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
Phastar's Vicky Marriott: Empowering women in STEM with empathy
Vicky Marriott’s journey from enjoying school math to heading a global team of statisticians at Phastar reveals her belief in the power of empathy and collaboration.
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of its cost-effectiveness.
Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Sanofi abandons phase 2 trial of Denali’s multiple sclerosis candidate
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
Women in STEM: Gitte Barknowitz’s journey to leading global initiatives
From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved out an exciting and unconventional career in science.
Women in Science: Sharmeen Roy - 'pharmacy is the perfect blend of all my favourite subjects'
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application.
Jane Koo on leading regulatory affairs at CTMC: A journey from mAbs to cellular therapies
Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization of innovative cellular therapies.
Antag Therapeutics gets FDA clearance to start clinical trials with new obesity drug
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.
Innovent and Ask Pharm join forces to commercialize third-generation lung cancer therapy
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
From CDMOs to artificial intelligence - what's the latest in the world of outsourcing?
Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of pharmaceutical outsourcing.
How specialized vendors improve patient recruitment success
Patient recruitment is a critical and often challenging aspect of clinical trials, particularly for biopharmaceutical companies seeking to accelerate drug development.
Women in Science - SCIEX Rebekah Sayers' on encouraging curiosity
Rebekah's father passed on his passion for science and problem solving to her and much of her childhood was spent doing fun hands-on activities from taking apart household mechanics to building rockets.
LoQus23 Therapeutics raises £35m to advance therapy for Huntington’s disease
The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.
CPHI 2024
CBD-based formulations from dsm-firmenich at CPHI 2024
At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.
Microbiome startup Sequentia Biotech heralds “new era” in omics with €10 million round
The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the development of its omics-based technology for use in biomedicine, agritech and food.
Women in Science - engineering life’s mysteries: Joaquima Guix Salichs’ journey
Joaquima Guix Salichs is the director of engineering and extraction technology at Bioiberica, where she leads a team of scientists focused on advancing extraction methods and solving large-scale industrial challenges.
Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns
The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.
FDA greenlights first treatment for Niemann-Pick disease type C
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for the treatment of the rare disease Niemann-Pick disease type C (NPC), which until now has lacked FDA-approved therapies.
Insilico Medicine claims phase 2 win for AI-designed drug
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.
NuraBio closes $140m fundraising to develop neuroprotective drugs
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.
Women in science - Alison O'Neill at YPrime on thinking out loud and collaborating
Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.
Boehringer Ingelheim score with phase 3 idiopathic pulmonary fibrosis win
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
F2G raises $100 million to combat innovation 'paucity' in antifungals
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
Vaxess' Rachel Sha - 'own the seat at the table that you have and have confidence'
Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have confidence and answer hard questions.
How modern trial designs propel cancer therapies to the market - interview
Clinical trials are becoming increasingly complex as emerging technologies such as immunotherapy enter the mainstream.